Low-Dose Aspirin for Preventing CVD: Another Neutral Study, but with Potential Differences by Race

This observational study found a trend towards benefit in whites but not in blacks.

The role of low-dose aspirin for primary prevention of cardiovascular disease (CVD) remains controversial, and few data exist on potential differences by race or ethnicity. To study this, investigators evaluated data on 65,231 American, non-Hispanic individuals without CVD (70% black; 30% white) from the population-based Southern Community Cohort Study. Participants were enrolled between 2002 and 2009 and aged 40 to 79 at baseline.

The authors calculated race/ethnicity-specific adjusted odds ratios for ischemic cardiac death according to aspirin use. Regardless of CVD risk, low-dose aspirin use was less common in blacks than whites (adjusted odds ratio, 0.79). A higher incidence of ischemic cardiac death was seen in whites than in blacks. Ov…

Reviewing Author

Karol E. Watson, MD, PhD, FACC

Disclosures

Consultant/Advisory BoardBoehringer Ingelheim; Amgen; Novartis; Lilly; Amarin

Speaker’s BureauBoehringer Ingelheim

Grant/Research SupportNIH

Editorial BoardsCirculation (Associate Editor)